Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Ltd
EMCURE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹24,695 cr, stock is ranked 293
Low RiskStock is 1.67x as volatile as Nifty
1,297.350.66% (-8.60)
1,297.350.66% (-8.60)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 7.91 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
PE Ratio
41.74
1Y Return
49.80%
Buy Reco %
67.65
Zydus Lifesciences Ltd
PE Ratio
31.44
1Y Return
93.63%
Buy Reco %
46.43
Cipla Ltd
PE Ratio
29.39
1Y Return
40.39%
Buy Reco %
75.00
Dr Reddy's Laboratories Ltd
PE Ratio
20.46
1Y Return
25.16%
Buy Reco %
40.74
Torrent Pharmaceuticals Ltd
PE Ratio
63.04
1Y Return
56.55%
Buy Reco %
78.57
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,274.01 | 4,911.74 | 5,130.86 | 5,067.35 | 5,918.86 | 6,031.72 | 6,715.24 | — | ||||||||
Raw Materials | 1,414.88 | 1,890.86 | 2,027.58 | 2,188.68 | 2,378.55 | 2,193.84 | 2,665.61 | — | ||||||||
| Power & Fuel Cost | 83.14 | 94.47 | 100.81 | 94.85 | 97.28 | 108.58 | 120.04 | |||||||||
| Employee Cost | 887.46 | 1,010.33 | 1,105.62 | 902.81 | 1,011.82 | 1,117.33 | 1,292.08 | |||||||||
| Selling & Administrative Expenses | 651.74 | 684.16 | 809.58 | 403.93 | 716.19 | 840.84 | 998.47 | |||||||||
| Operating & Other expenses | 542.55 | 411.47 | 404.50 | 420.10 | 321.63 | 550.19 | 362.26 | |||||||||
EBITDA | 694.24 | 820.45 | 682.77 | 1,056.98 | 1,393.39 | 1,220.94 | 1,276.78 | — | ||||||||
| Depreciation/Amortization | 228.05 | 267.17 | 320.83 | 249.99 | 244.86 | 260.12 | 312.41 | — | ||||||||
| PBIT | 466.19 | 553.28 | 361.94 | 806.99 | 1,148.53 | 960.82 | 964.37 | — | ||||||||
| Interest & Other Items | 175.73 | 222.66 | 256.60 | 154.94 | 175.98 | 213.61 | 237.15 | — | ||||||||
| PBT | 290.46 | 330.62 | 105.34 | 652.05 | 972.55 | 747.21 | 727.22 | — | ||||||||
| Taxes & Other Items | 115.37 | 135.55 | 21.73 | 233.44 | 310.35 | 215.20 | 229.04 | — | ||||||||
| Net Income | 175.09 | 195.07 | 83.61 | 418.61 | 662.20 | 532.01 | 498.18 | — | ||||||||
| EPS | 9.68 | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.52 | — | ||||||||
| DPS | 3.50 | 3.50 | 0.00 | 1.00 | 3.00 | 2.00 | — | — | ||||||||
| Payout ratio | 0.36 | 0.32 | 0.00 | 0.04 | 0.08 | 0.07 | 0.00 | — |
Company Updates
Peers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Emcure Pharmaceuticals Ltd | 49.57 | 7.91 | — |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare EMCURE with any stock or ETFCompare EMCURE with any stock or ETF
EMCURE
Shareholdings
Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Jul 2024
Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNews & Opinions
Articles & Videos
Hmm, looks like data is unavailable here. Please come back after some time.
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.45%, vs industry avg of 8.96%
Decreasing Market Share
Over the last 5 years, market share decreased from 2.17% to 1.83%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 20.63%, vs industry avg of 15.15%